• Careers

  • News

  • Information

  • Report an Adverse Event

  • Pfizer Inc.

  • News

  • Pfizer Pro

  • Sitemap

  • Contact Us

  • Terms of Use

  • Privacy Policy

Pfizer

Pfizer is dedicated to improving your health and wellness.

recent news

11.23.2020

News Article with image

11.23.2020

News Article without image

11.23.2020

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors

11.23.2020

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors

11.23.2020

Pfizer Doses First Participant in Phase 3 Study Evaluating anti-TFPI Investigational Therapy, Marstacimab, for People With Severe Hemophilia A and B With or Without Inhibitors

Editable Link Text
Our PURPOSEAbout Pfizer PakistanCommitment to Global HealthMessage from the CEOOur Purpose & Valuesour scienceInternal MedicineAnti-InfectivesOncologyVaccinesInflammation and Immunologyour productsour manufacturingconnect with us